K963851(1.10+2)



JAN 2 6 2007

# 510(k) Summary

SIV(K) Number:	510	<b>(k)</b>	Number:		
----------------	-----	------------	---------	--	--

**Date Prepared** 

December 27, 2006

**Submitter Information** 

Submitter's Name/

Address:

Vascular Solutions, Inc.

6464 Sycamore Court

Minneapolis, MN 55369

Establishment Registration

2134812

Contact Person:

Patrice Stromberg

Sr. Regulatory Affairs Associate

(763) 656-4243 telephone

(763) 656-4200 fax

pstromberg@vascularsolutions.com

**Device Information** 

Trade Name:

Auto-Fill® Syringe Kit

Classification Name:

Piston Syringe; Intravascular Administration Set

Product Codes:

FMF, FPA

Regulations:

Class II, 880.5860, 880.5440

#### **Performance Standards**

No performance standards applicable to this product have been developed under Section 514 of the Act.

K463851(1.20F2)

#### **Predicate Device(s)**

- Auto-Fill<sup>TM</sup> Syringe Kit marketed by Vascular Solutions, Inc. (K033721)
- IV Administration Set marketed by DeRoyal® (Codan USA) (pre-amendment device)
- Angiographic Control Syringe, marketed by DeRoyal, Inc. (CDI) (K920135)
- L.O.N. Pressure Monitoring Lines, CPC Lines, Administration, marketed by DeRoyal (CDI) (K853099)
- Multi-Ad Fluid Dispensing System, marketed by B. Braun Medical, K792227

#### **Device Description**

The Auto-Fill Syringe Kit contains disposable components that may be used to deliver dilute lidocaine solutions into subcutaneous tissues for the purposes of local anesthesia. The kit provides an extension tubing mechanism to conveniently refill a 12cc syringe from an IV bag eliminating the need for multiple reconnections to the solution container.

The kit contains the following items:

- 12cc Control Syringe
- IV tubing with spike, dual check valve, and roller clamp
- Extension line (various lengths ranging from 6" to 48")

#### Intended Use/Indications for Use

The AutoFill® Syringe Kit is indicated for the introduction of dilute lidocaine solutions into subcutaneous tissues for the purposes of tumescent local anesthesia.

#### **Summary of Non-Clinical Testing**

<u>Performance Testing</u>: The static and dynamic pressure capabilities of the extension tubing for the Auto-Fill Syringe Kit were tested. The extension tubing met the specified design and performance requirements.

Biocompatibility Testing: The material in the components used to create the Auto-Fill Syringe Kit has been demonstrated to be biocompatible through biocompatibility testing performed by the original manufacturers.

#### **Summary of Clinical Testing**

No clinical evaluations of this product have been performed.

### **Statement of Equivalence**

Through the data and information presented, Vascular Solutions considers the Auto-Fill® Syringe Kit to be substantially equivalent to the identified predicate devices based on a comparison of the indications for use and the technological characteristics of the supplied components.





Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Patrice Stromberg Senior Regulatory Affairs Associate Vascular Solutions, Incorporated 6464 Sycamore Court North Minneapolis, Minnesota 55369

JAN 2 6 2007

Re: K063851

Trade/Device Name: Auto-Fill Syringe Kit, Model 7600

Regulation Number: 21 CFR 880.5860

Regulation Name: Piston Syringe

Regulatory Class: II Product Code: FMF, FPA Dated: December 27, 2006 Received: December 28, 2006

## Dear Ms. Stromberg:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

# **Indications for Use Statement**

510(k) Number	r (if known):		
Device Name:	Auto-Fill® Syri	nge Kit	
Indications for	Use:		
The Aussolution	to-Fill® Syringe is into subcutaned	Kit is indicated ous tissues for the	for the introduction of dilute lidocaine are purposes of tumescent local anesthesia
	·	•	
Prescription Use (Part 21 CFR 80	X 11 Subpart D)	AND/OR	Over-The-Counter Use(21 CFR 801 Subpart C)
	(PLEASE DO CONTINUE (	NOT WRITE E ON ANOTHER	BELOW THIS LINE – PAGE IF NEEDED)
			Device Evaluation (ODE)
(5")	Vision Sign-Cff)		
infe	ction Control, Den	ology, General Ho Ital Devices	ospital,
51 <i>0</i>	(k) Number: <u>ky</u>	P63857	